We recently published our article Top 5 Stocks Delivering Big-Time Gains Today. To read the full story, you can go directly to Top 10 Stocks Delivering Big-Time Gains Today. In this article, we discuss Immunovant Inc. (NASDAQ:IMVT) as one of the stocks gaining attention, and here’s a closer look at why it stands out in today’s market.

Wall Street Finds Its Footing Again

Wall Street had one of those sessions that reminded investors why momentum can shift quickly in the stock market. After weeks of watching economic data, earnings reports, interest rate expectations, and corporate headlines pull equities in different directions, investors finally saw a broad-based rally on Wednesday, with all three major U.S. stock market indices closing firmly in positive territory.

The Nasdaq Composite led the charge with a 1.54 percent gain, helped by renewed appetite for growth stocks, technology names, artificial intelligence-related plays, and companies with strong company-specific catalysts. The Dow Jones Industrial Average followed with a 1.31 percent advance, while the S&P 500 climbed 1.08 percent, giving the broader market a much-needed boost and reinforcing the idea that investor sentiment can turn sharply when the right mix of news, volume, and institutional buying enters the picture.

The Bigger Story Was Beneath the Indices

For market watchers, Wednesday’s rally was not just about the indices. The more interesting story happened beneath the surface, where individual stocks delivered outsized moves that stood out even against a strong day for the broader market. In every trading session, there are always names that rise with the tide, but the stocks featured in this article did more than simply follow Wall Street higher.

These were companies that attracted serious attention because of fresh developments, unusual trading volume, earnings momentum, strategic updates, analyst reactions, sector strength, or investor speculation around future growth. That is why this list focuses on the ten top-performing stocks on Wednesday, using a screen that considered companies with at least $2 billion in market capitalization and at least 5 million shares in trading volume.

Why Volume and Market Cap Matter

That filter matters. It removes many thinly traded micro-cap stocks that can swing wildly on small orders and instead highlights more liquid, widely followed companies where price action may reflect stronger institutional interest, meaningful market participation, or a broader change in investor perception.

There is an old Wall Street saying that “volume confirms price,” and Wednesday’s biggest movers offered a useful reminder of that principle. A stock jumping sharply on light trading can be interesting, but a stock rising on heavy volume often tells a deeper story. It suggests that investors are not merely reacting casually; they may be repositioning around new information. That information can come from many places: earnings results, guidance revisions, takeover speculation, regulatory news, product launches, artificial intelligence exposure, cost-cutting plans, debt refinancing, biotech trial updates, or renewed optimism in a beaten-down sector.

What Investors Should Watch Next

Wednesday’s stock market gain also came at a time when investors remain highly selective. The market has rewarded companies that can show real revenue growth, improving margins, strong cash flow, artificial intelligence opportunities, better-than-expected earnings, or credible turnaround plans. At the same time, it has punished weak guidance, heavy debt loads, slowing demand, and unclear business models.

This article breaks down the ten stocks that soared higher on Wednesday and explains the likely reasons behind their gains. Some may have rallied because of strong earnings. Others may have benefited from bullish analyst coverage, sector rotation, short-covering, product news, or renewed investor confidence. Whatever the cause, these stocks became some of the most closely watched names in the U.S. stock market during the session.

For investors searching for the best-performing stocks today, top stock market gainers, Wall Street movers, high-volume stocks, Nasdaq gainers, S&P 500 winners, and companies making major market moves, Wednesday’s action offers plenty to examine. The rally showed that even in a cautious market, investors are still willing to chase strength when the story is compelling, the volume is real, and the catalyst is strong enough to change the conversation.

CHECK THIS OUT: 10 Cheap Stocks That Could Deliver 100%+ Gains Over the Next 10 Years and Top 10 American AI Stocks With 30% to 100% Upside Potential.

Our Methodology

To come up with the ranking, the article screened Wednesday’s top-performing U.S.-listed stocks and focused only on companies with a market capitalization of at least $2 billion and trading volume of at least 5 million shares. This helped filter out thinly traded and highly speculative micro-cap names, allowing the list to focus on liquid, widely followed stocks that posted significant gains during the session. The final ranking was then arranged based on each stock’s percentage gain for the day, while also considering the company-specific developments, market catalysts, and trading activity that helped explain the move.

Top 5 Stocks Delivering Big-Time Gains Today

1. Immunovant Inc. (NASDAQ:IMVT)

Immunovant Inc. (NASDAQ: IMVT) claimed the top spot after soaring 35.26 percent on Wednesday to close at $35.56 per share, marking its strongest move among the stocks in this ranking. The rally pushed the stock to a new five-year high, with shares reaching as much as $36.28 intraday before giving back a small portion of the gains into the close. For investors searching for the best biotech stocks today, top healthcare stocks, clinical trial stocks, rheumatoid arthritis treatment stocks, FDA approval stocks, and Nasdaq gainers, Immunovant was the clear headline name of the session.

The surge came after the company reported stellar clinical trial results for IMVT-1402, its drug candidate for difficult-to-treat rheumatoid arthritis. In biotech investing, clinical data can be one of the most powerful stock catalysts because it can immediately change how the market values a company’s pipeline. A successful trial result can strengthen confidence in a drug candidate, improve expectations for regulatory progress, and increase the perceived likelihood of eventual commercial launch. That is exactly what appeared to happen with Immunovant on Wednesday.

According to the company, IMVT-1402 showed clinically meaningful response rates at Week 16, including 72.7 percent ACR20, 54.5 percent ACR50, and 35.8 percent ACR70. These figures are important because ACR20, ACR50, and ACR70 are commonly used measures in rheumatoid arthritis trials to assess improvement in symptoms. A higher number generally indicates a stronger level of patient response. For investors, the results suggested that IMVT-1402 may have real clinical potential in a hard-to-treat patient population, which helped explain the dramatic jump in the stock price.

The company said it would announce further updates on the program in the second half of 2026. That gives investors a clear timeline to watch and potentially sets up another catalyst later in the year. Biotech stocks often trade not only on current data, but also on the next expected update. In Immunovant’s case, Wednesday’s rally may reflect both the strength of the latest trial results and the market’s anticipation of what could come next if additional data continue to support the drug’s profile.

Wall Street also responded positively. Stifel reiterated its “buy” recommendation and maintained a $49 price target on Immunovant, reflecting confidence that the results could eventually move the drug closer to regulatory approval and commercial launch. Analyst support can matter significantly after biotech trial results because it helps investors interpret the commercial and regulatory implications of clinical data. In this case, Stifel’s bullish stance appeared to strengthen the market’s conviction that the trial results were not merely encouraging, but potentially meaningful for the company’s long-term value.

There was still a financial concern in the background. Immunovant reported that its first-quarter net loss widened by 38.9 percent to $147.8 million from $106.4 million in the same period last year. That is a reminder that even strong biotech stories can carry heavy cash burn, especially when companies are funding clinical trials, research programs, and development pipelines. But on Wednesday, investors were clearly more focused on the clinical upside than the widening loss.

Immunovant’s move was the kind of biotech rally that market watchers pay attention to because it was driven by trial data, analyst confidence, and a large potential treatment opportunity. Among Wednesday’s top stock market gainers, IMVT stood out as the clearest example of how a single clinical update can dramatically reprice a healthcare stock. For now, the company’s next major challenge is simple but difficult: convert promising clinical results into regulatory progress, commercial readiness, and eventually, real revenue.

YOU MUST READ THIS: Top 10 Cheap Large-Cap Stocks Under $100 to Buy Now

Disclosure: No material interests to disclose. This article was originally published on Global Market Bulletin.